Share Twitter LinkedIn Facebook Email Nancy A. Dawson MD, Professor of Medicine at Lombardi Cancer Center shares on how to decide between combinations of immuno-oncology (I-O) and TKIs for treating 1st line renal cell carcinoma (RCC).
MOASC Awards $25,000 Research Grant from AVEO Oncology to Dr. Peter Zang, MD of City of Hope 2025 Cary Presant, MD Investigator Award Prostate 4 Mins Read
Overview of SYNC-T Technology from Syncromune in Prostate Cancer Treatment – Charles Link, MD Prostate 2 Mins Read